Correlation Engine 2.0
Clear Search sequence regions

  • humans (1)
  • ipilimumab (6)
  • patients (1)
  • t cell (1)
  • Sizes of these terms reflect their relevance to your search.

    Ipilimumab with and without anti-Programmed Death 1 (PD-1) improved overall survival (OS) in melanoma. Despite this, the optimal dose and therapeutic mechanism of ipilimumab in patients remains unclear. KEYNOTE-029 and other studies suggest that low-dose ipilimumab with anti-PD1 maintains efficacy while decreasing toxicity, emphasizing T-cell trafficking and reinvigoration as likely mechanisms. See related article by Long et al., p. 5280. ©2021 American Association for Cancer Research.


    Max Jameson-Lee, Jason J Luke. Ipilimumab Combination Dosing: Less is More. Clinical cancer research : an official journal of the American Association for Cancer Research. 2021 Oct 01;27(19):5153-5155

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 34341015

    View Full Text